<DOC>
	<DOC>NCT02709538</DOC>
	<brief_summary>To evaluate the long term safety and efficacy of GSP 301 NS compared to 2 placebo NS formulations for the treatment of perennial allergic rhinitis (patients 12 years of age and older)</brief_summary>
	<brief_title>Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<criteria>1. Aged â‰¥12 years and older inclusive of either sex. 2. Documented clinical history of PAR (for at least 2 years preceding the Screening Visit [Visit 1]) and exhibiting a documented positive skin prick test (wheal diameter at least 3 mm greater than negative diluent control wheal) to at least 1 allergen known to induce PAR. Documentation of a positive result within 12 months prior to the Screening Visit (Visit 1) is acceptable. 1. Pregnant or lactating women. 2. History of anaphylaxis and/or other severe local reaction(s) to skin testing. 3. History of positive test for HIV, Hepatitis B or Hepatitis C infection. 4. Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip. 5. Subjects with an active pulmonary disorder or infection. 6. Subjects with posterior subcapsular cataracts or glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>